Abstract:Background Intratumoral delivery of immunotherapeutics represents a compelling solution to directly address local barriers to tumor immunity. However, we have previously shown that off-target delivery is a substantial problem during intratumoral injections; this can lead to diminished drug efficacy and systemic toxicities. We have identified three variables that influence intratumoral drug delivery: injection technique, drug formulation and tumor microenvironment. The purpose of this study was to characterize the impact of modifications in each variable on intratumoral drug delivery and immunotherapy efficacy. Methods Intratumoral injections were performed in a hybrid image-guided intervention suite with ultrasound, fluoroscopy and CT scanning capabilities in both rat and mouse syngeneic tumor models. Intratumoral drug distribution was quantified by CT volumetric imaging. The influence of varying needle design and hydrogel-based drug delivery on the immune response to a stimulator of interferon genes (STING) agonist was evaluated using flow cytometry and single cell RNA sequencing. We also evaluated the influence of tumor stiffness on drug injection distribution. Results Variations in needle design, specifically with the use of a multiside hole needle, led to approximately threefold improvements in intratumoral drug deposition relative to conventional end-hole needles. Likewise, delivery of a STING agonist through a multiside hole needle led to significantly increased expression of type I interferon-associated genes and ‘inflammatory’ dendritic cell gene signatures relative to end-hole STING agonist delivery. A multidomain peptide-based hydrogel embedded with a STING agonist led to substantial improvements in intratumoral deposition; however, the hydrogel was noted to generate a strong immune response against itself within the target tumor. Evaluation of tumor stroma on intratumoral drug delivery revealed that there was a greater than twofold improvement in intratumoral distribution in soft tumors (B16 melanoma) compared with firm tumors (MC38 colorectal). Conclusions Injection technique, drug formulation and tumor stiffness play key roles in the accurate delivery of intratumoral immunotherapeutics.

Advances and Challenges in Interventional Immuno-Oncology Locoregional Therapies

Advancing cancer immunotherapy through emerging intratumoral delivery and biomedical imaging technologies

Emerging Strategies for Local Delivery of Immune Checkpoint Inhibitors to Potentiate Cancer Immunotherapy: Current Status and Future Prospects

Engineering the Tumor Immune Microenvironment through Minimally Invasive Interventions

Immunomodulatory Effect of Locoregional Therapy in the Tumor Microenvironment

Combined with Interventional Therapy, Immunotherapy Can Create a New Outlook for Tumor Treatment.

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Locoregional drug delivery for cancer therapy: Preclinical progress and clinical translation

Intratumoral delivery of immunotherapy to treat breast cancer: current development in clinical and preclinical studies

Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments

Advances in Engineering Local Drug Delivery Systems for Cancer Immunotherapy

Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders

Immunotherapies for locally aggressive cancers

Locoregional Therapies in Immunologically "Cold" Tumors: Opportunities and Clinical Trial Design Considerations

Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy

Intratumoural administration and tumour tissue targeting of cancer immunotherapies

Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma

Contemporary Approaches to Immunotherapy of Solid Tumors

Localized delivery of immunotherapeutics: A rising trend in the field

Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma

Act Local, Think Global: IR and Its Role in Immuno-Oncology in Hepatocellular Carcinoma